On January 15, the Subcommittee on Health of the Committee on Energy and Commerce held its first ever legislative hearing to address federal cannabis policies.  The subcommittee invited witness from three different agencies to provide testimony: Matthew K. Strait, Drug Enforcement Administration (“DEA”); Douglas Throckmorton, Food and Drug Administration(“FDA”); and Nora D. Volkow, National Institutes on Drug Abuse (“NIDA”).  The hearing lasted over three hours and included several areas of discussion.  Here are some highlights:…
In a case of first impression, the New Jersey Appellate Division determined that employers in the state must reimburse employees for medical cannabis following a workplace accident, despite federal prohibitions against cannabis distribution.  The January 13, 2020 decision in Hager v. M&K Construction, Case No. A-0102-18T3, is the first time a court in the state has required reimbursement for a cannabis prescription in the workers’ compensation context, and may signal a fresh judicial focus…
An employer ordered to reimburse a worker for his purchase of medical marijuana – as part of a workers’ compensation claim – is not in danger of violating the federal Controlled Substances Act, according to an important decision rendered by the New Jersey Appellate Division this week. In Vincent Hager v. M&K Construction, Case No. A-0102-18T3 (N.J. App. Div.), the court grappled with a potential conflict between the Controlled Substances Act (“CSA”), 21 U.S.C. §…